



JPW

PATENT
ATTORNEY DOCKET NO. 00786/434002

Certificate of Mailing: Date of Deposit: 12/13/06

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Seth Eckstein

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Berthiaume et al.	Confirmation No.:	2396
Serial No.:	10/531,001	Art Unit:	3736
Filed:	November 10, 2005	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	COMPOSITIONS, SOLUTIONS, AND METHODS USED FOR TRANSPLANTATION		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449. Of these references, eight journal articles are enclosed, and abstracts are submitted for the remaining, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 13 December 2006



Karen L. Elbing, Ph.D.
Reg. No. 35,238


Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/531,001
(37 C.F.R. § 1.98(b))		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,094,965	June 13, 1978	Layne et al.			
	4,192,916	March 11, 1980	Melby et al.			
	4,243,678	January 6, 1981	Krastinat			
	4,410,507	October 18, 1983	Chia et al.			
	4,604,234	August 5, 1986	Fujii et al.			
	4,663,166	May 5, 1987	Veech			
	4,707,369	November 17, 1987	Suresky			
	4,778,787	October 18, 1988	Catsimpoilas et al.			
	4,835,102	May 30, 1989	Bell et al.			
	4,895,558	January 23, 1990	Cham			
	4,914,032	April 3, 1990	Kuri-Harcuch et al.			
	4,923,442	May 8, 1990	Segall et al.			
	4,963,370	October 16, 1990	Uchida et al.			
	4,971,952	November 20, 1990	Bentz et al.			
	5,002,661	March 26, 1991	Chick et al.			
	5,030,105	July 9, 1991	Kuri-Harcuch et al.			
	5,116,493	May 26, 1992	Chick et al.			
	5,116,494	May 26, 1992	Chick et al.			
	5,118,493	June 2, 1992	Kelley et al.			
	5,130,230	July 14, 1992	Segall et al.			
	RE34,077	September 22, 1992	Segall et al.			


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 24

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,182,106	January 26, 1993	Mezrow et al.			
	5,186,923	February 16, 1993	Piwnica-Worms et al.			
	5,237,056	August 17, 1993	Fischbach			
	5,260,067	November 9, 1993	Zheng			
	5,272,180	December 21, 1993	Hashimoto et al.			
	5,277,897	January 11, 1994	Piwnica-Worms et al.			
	5,298,417	March 29, 1994	Cancedda et al.			
	5,320,846	June 14, 1994	Bistran et al.			
	5,322,775	June 21, 1994	Clark et al.			
	5,354,557	October 11, 1994	Oppermann et al.			
	5,362,406	November 8, 1994	Gsell et al.			
	5,366,894	November 22, 1994	Clark et al.			
	5,389,621	February 14, 1995	Abdel-Rahman et al.			
	5,399,493	March 21, 1995	Emerson et al.			
	5,405,742	April 11, 1995	Taylor			
	5,407,428	April 18, 1995	Segall et al.			
	5,411,730	May 2, 1995	Kirpotin et al.			
	5,411,751	May 2, 1995	Crissinger et al.			
	5,437,994	August 1, 1995	Emerson et al.			
	5,460,945	October 24, 1995	Springer et al.			
	5,468,845	November 21, 1995	Oppermann et al.			


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,470,879	November 28, 1995	Sauvaire et al.			
	5,475,086	December 12, 1995	Tobin et al.			
	5,476,995	December 19, 1995	Clark et al.			
	5,514,536	May 7, 1996	Taylor			
	5,521,076	May 28, 1996	Mulligan et al.			
	5,521,291	May 28, 1996	Curiel et al.			
	5,529,982	June 25, 1996	Carlino et al.			
	5,530,114	June 25, 1996	Bennett et al.			
	5,536,241	July 16, 1996	Zapol			
	5,571,783	November 5, 1996	Montagne et al.			
	5,571,797	November 5, 1996	Ohno et al.			
	5,571,801	November 5, 1996	Segall et al.			
	5,580,776	December 3, 1996	Wilson et al.			
	5,587,368	December 24, 1996	Javitt			
	5,591,629	January 7, 1997	Rodriguez et al.			
	5,595,909	January 21, 1997	Hu et al.			
	5,599,659	February 4, 1997	Brasile et al.			
	5,605,801	February 25, 1997	Cousens et al.			
	5,605,930	February 25, 1997	Samid			
	5,612,034	March 18, 1997	Pouletty et al.			
	5,612,212	March 18, 1997	Gewirtz			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 4 of 24

<p>SUBSTITUTE FORM PTO-1449 (MODIFIED)</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,613,944	March 25, 1997	Segall et al.			
	5,618,531	April 8, 1997	Cherksey			
	5,618,709	April 8, 1997	Gewirtz et al.			
	5,622,857	April 22, 1997	Goffe			
	5,631,237	May 20, 1997	Dzau et al.			
	5,635,187	June 3, 1997	Bathurst et al.			
	5,635,344	June 3, 1997	Garcia et al.			
	5,635,386	June 3, 1997	Palsson et al.			
	5,637,315	June 10, 1997	Zern et al.			
	5,641,669	June 24, 1997	Cousens et al.			
	5,646,043	July 8, 1997	Emerson et al.			
	5,650,504	July 22, 1997	Bartley et al.			
	5,654,404	August 5, 1997	Roos et al.			
	5,656,431	August 12, 1997	Cousens et al.			
	5,667,764	September 16, 1997	Kopia et al.			
	5,670,147	September 23, 1997	Emerson et al.			
	5,670,351	September 23, 1997	Emerson et al.			
	5,670,488	September 23, 1997	Gregory et al.			
	5,674,978	October 7, 1997	Tobin et al.			
	5,698,403	December 16, 1997	Cousens et al.			
	5,698,536	December 16, 1997	Segall et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,699,793	December 23, 1997	Brasile			
	5,702,881	December 30, 1997	Brasile et al.			
	5,703,048	December 30, 1997	Roos et al.			
	5,705,626	January 6, 1998	Tobin et al.			
	5,714,345	February 3, 1998	Clark			
	5,716,934	February 10, 1998	Bartley et al.			
	5,719,174	February 17, 1998	Sainsbury et al.			
	5,723,281	March 3, 1998	Segall et al.			
	5,733,879	March 31, 1998	Rosseneu et al.			
	5,733,894	March 31, 1998	Segall et al.			
	5,734,039	March 31, 1998	Calabretta et al.			
	5,744,047	April 28, 1998	Gsell et al.			
	5,747,071	May 5, 1998	Segall et al.			
	5,750,103	May 12, 1998	Cherksey			
	5,756,264	May 26, 1998	Schwartz et al.			
	5,770,226	June 23, 1998	Hughes, Jr. et al.			
	5,770,580	June 23, 1998	Ledley et al.			
	5,773,431	June 30, 1998	Javitt			
	5,786,213	July 28, 1998	Singh et al.			
	5,792,743	August 11, 1998	Schachner			
	5,792,751	August 11, 1998	Ledley et al.			


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,801,200	September 1, 1998	Bucala et al.			
	5,804,405	September 8, 1998	Ahlfors			
	5,824,303	October 20, 1998	Bartley et al.			
	5,827,729	October 27, 1998	Naughton et al.			
	5,830,640	November 3, 1998	Patierno et al.			
	5,834,589	November 10, 1998	Meruelo et al.			
	5,837,693	November 17, 1998	German et al.			
	5,843,024	December 1, 1998	Brasile			
	5,843,994	December 1, 1998	Samid			
	5,846,740	December 8, 1998	Tobin et al.			
	5,847,088	December 8, 1998	Cousens et al.			
	5,849,686	December 15, 1998	Kuberasampath et al.			
	5,849,991	December 15, 1998	d'Apice et al.			
	5,851,818	December 22, 1998	Huang et al.			
	5,858,990	January 12, 1999	Walsh			
	5,869,462	February 9, 1999	Dzau			
	5,877,289	March 2, 1999	Thorpe et al.			
	5,877,309	March 2, 1999	McKay et al.			
	5,882,877	March 16, 1999	Gregory et al.			
	5,883,082	March 16, 1999	Bennett et al.			
	5,883,124	March 16, 1999	Samid			


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,885,829	March 23, 1999	Mooney et al.			
	5,885,971	March 23, 1999	German et al.			
	5,891,468	April 6, 1999	Martin et al.			
	5,908,624	June 1, 1999	Scott et al.			
	5,925,564	July 20, 1999	Schwartz et al.			
	5,935,860	August 10, 1999	Patierno et al.			
	5,942,248	August 24, 1999	Barnwell			
	5,961,459	October 5, 1999	Kaul et al.			
	5,962,021	October 5, 1999	Hughes, Jr. et al.			
	5,968,737	October 19, 1999	Ali-Osman et al.			
	5,972,248	October 26, 1999	Stahrfeldt			
	5,972,894	October 26, 1999	Sinackevich et al.			
	5,977,083	November 2, 1999	Burcoglu			
	5,977,308	November 2, 1999	Cousens et al.			
	5,981,194	November 9, 1999	Jefferies et al.			
	5,981,279	November 9, 1999	Weiss			
	5,981,568	November 9, 1999	Kunz et al.			
	5,985,260	November 16, 1999	Shanbrom			
	5,985,854	November 16, 1999	Kozak			
	5,994,109	November 30, 1999	Woo et al.			
	5,997,898	December 7, 1999	Unger			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,998,366	December 7, 1999	Tobin et al.			
	6,001,606	December 14, 1999	Ruben et al.			
	6,004,555	December 21, 1999	Thorpe et al.			
	6,004,579	December 21, 1999	Bathurst et al.			
	6,004,936	December 21, 1999	Kisilevsky			
	6,004,944	December 21, 1999	Rothman et al.			
	6,008,014	December 28, 1999	Gimeno et al.			
	6,008,049	December 28, 1999	Naughton et al.			
	6,011,019	January 4, 2000	Thomas et al.			
	6,011,139	January 4, 2000	Tobin et al.			
	6,017,734	January 25, 2000	Summers et al.			
	6,017,756	January 25, 2000	Draper			
	6,024,698	February 15, 2000	Brasile			
	6,027,722	February 22, 2000	Hodgson			
	6,030,822	February 29, 2000	Lechner et al.			
	6,030,833	February 29, 2000	Seebach et al.			
	6,033,884	March 7, 2000	Woo et al.			
	6,036,955	March 14, 2000	Thorpe et al.			
	6,045,794	April 4, 2000	Cousens et al.			
	6,048,515	April 11, 2000	Kresse et al.			
	6,054,320	April 25, 2000	Patierno et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.	00786/434002
Serial No.	10/531,001
Applicant	Berthiaume et al.
Filing Date	Nov. 10, 2005
Group	3736
IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,054,467	April 25, 2000	Gjerset			
	6,060,048	May 9, 2000	Cherksey			
	6,066,626	May 23, 2000	Yew et al.			
	6,077,837	June 20, 2000	Kozak			
	6,080,551	June 27, 2000	Doyle et al.			
	6,084,085	July 4, 2000	Baserga et al.			
	6,087,129	July 11, 2000	Newgard et al.			
	6,087,167	July 11, 2000	Bartley et al.			
	6,090,621	July 18, 2000	Kavanaugh et al.			
	6,093,399	July 25, 2000	Thorpe et al.			
	6,093,567	July 25, 2000	Gregory et al.			
	6,096,725	August 1, 2000	Simon et al.			
	6,099,836	August 8, 2000	Cousens et al.			
	6,099,841	August 8, 2000	Hillan et al.			
	6,103,233	August 15, 2000	Pouletty et al.			
	6,107,331	August 22, 2000	MacLean et al.			
	6,110,504	August 29, 2000	Segall et al.			
	6,110,707	August 29, 2000	Newgard et al.			
	6,110,744	August 29, 2000	Fang et al.			
	6,121,416	September 19, 2000	Clark et al.			
	6,126,945	October 3, 2000	Terman et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,127,119	October 3, 2000	Stephens et al.			
	6,132,729	October 17, 2000	Thorpe et al.			
	6,132,730	October 17, 2000	Thorpe et al.			
	6,133,026	October 17, 2000	Huang et al.			
	6,133,246	October 17, 2000	McKay et al.			
	6,136,796	October 24, 2000	Kozak			
	6,139,873	October 31, 2000	Hughes, Jr. et al.			
	6,146,625	November 14, 2000	Cousens et al.			
	6,146,847	November 14, 2000	Goffe et al.			
	6,150,168	November 21, 2000	Woo et al.			
	6,156,321	December 5, 2000	Thorpe et al.			
	6,159,464	December 12, 2000	Glorioso et al.			
	6,165,737	December 26, 2000	Wang et al.			
	6,165,979	December 26, 2000	Kozhemyakin et al.			
	6,165,990	December 26, 2000	Singh et al.			
	6,166,089	December 26, 2000	Kozak			
	6,171,787	January 9, 2001	Wiley			
	6,171,856	January 9, 2001	Thigpen et al.			
	6,176,842	January 23, 2001	Tachibana et al.			
	6,177,403	January 23, 2001	Stedman			
	6,177,554	January 23, 2001	Woo et al.			


EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,180,613	January 30, 2001	Kaplitt et al.			
	6,194,176	February 27, 2001	Newgard et al.			
	6,194,191	February 27, 2001	Zhang et al.			
	6,197,751	March 6, 2001	Malinda et al.			
	6,197,754	March 6, 2001	Hung et al.			
	6,203,790	March 20, 2001	Cousens et al.			
	6,203,991	March 20, 2001	Nabel et al.			
	6,207,153	March 27, 2001	Dan et al.			
	6,207,642	March 27, 2001	Wiley			
	6,207,856	March 27, 2001	Veech			
	6,207,876	March 27, 2001	Kellems et al.			
	6,218,182	April 17, 2001	Naughton et al.			
	6,221,351	April 24, 2001	Terman			
	6,221,850	April 24, 2001	McKay et al.			
	6,224,858	May 1, 2001	Mulligan et al			
	6,224,903	May 1, 2001	Martin et al.			
	6,245,019	June 12, 2001	Kamiyama			
	6,245,317	June 12, 2001	DeGrado et al.			
	6,248,722	June 19, 2001	Morishita et al.			
	6,251,857	June 26, 2001	Kozhemyakin et al.			
	6,251,865	June 26, 2001	Clark et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	



INSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,252,664	June 26, 2001	Barbera-Guillem			
	6,255,289	July 3, 2001	German et al.			
	6,258,828	July 10, 2001	Towart et al.			
	6,261,537	July 17, 2001	Klaveness et al.			
	6,264,917	July 24, 2001	Klaveness et al.			
	6,264,943	July 24, 2001	Cherksey			
	6,271,436	August 7, 2001	Piedrahita et al.			
	6,274,568	August 14, 2001	Schnaar et al.			
	6,274,618	August 14, 2001	MacLean et al.			
	6,277,586	August 21, 2001	Tobin et al.			
	6,280,994	August 28, 2001	Sheppard			
	6,287,788	September 11, 2001	Bard et al.			
	6,287,863	September 11, 2001	Hodgson			
	6,288,039	September 11, 2001	Patierno et al.			
	6,288,106	September 11, 2001	Pearson et al.			
	6,290,949	September 18, 2001	French et al.			
	6,306,398	October 23, 2001	Bathurst et al.			
	6,306,421	October 23, 2001	Kunz et al.			
	6,312,924	November 6, 2001	Presnell et al.			
	6,316,038	November 13, 2001	Veech			
	6,316,255	November 13, 2001	Mulligan et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,316,416	November 13, 2001	Patierno			
	6,319,914	November 20, 2001	Simpkins et al.			
	6,321,909	November 27, 2001	Wicomb et al.			
	6,323,237	November 27, 2001	Veech			
	6,326,198	December 4, 2001	Emerson et al.			
	6,326,201	December 4, 2001	Fung et al.			
	6,329,175	December 11, 2001	Conklin et al.			
	6,329,197	December 11, 2001	Bard et al.			
	6,331,289	December 18, 2001	Klaveness et al.			
	6,333,034	December 25, 2001	Gupta-Bansal et al.			
	6,333,051	December 25, 2001	Kabanov et al.			
	6,333,110	December 25, 2001	Barbera-Guillem			
	6,333,396	December 25, 2001	Filpula et al.			
	6,335,321	January 1, 2002	Patierno et al.			
	6,338,845	January 15, 2002	Terman			
	6,340,703	January 22, 2002	Kelly			
	6,344,323	February 5, 2002	Seifert			
	6,348,327	February 19, 2002	Gorman et al.			
	6,355,474	March 12, 2002	Hidvegi et al.			
	6,355,629	March 12, 2002	Kozak			
	6,355,670	March 12, 2002	Maclean et al.			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,358,915	March 19, 2002	Patierno et al.			
	6,358,989	March 19, 2002	Kunz et al.			
	6,359,194	March 19, 2002	Galvin et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Adam et al., "The outcome of steatotic grafts in liver transplantation," <i>Transplant Proc.</i> 23: 1538-1540 (1991) (Abstract).
	Ahmad et al., "Xenon-133 retention in hepatic steatosis-correlation with liver biopsy in 45 patients: concise communication," <i>J Nucl Med.</i> 20: 397-401 (1979) (Abstract).
	Amersi et al., "Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury," <i>J Clin Invest.</i> 104: 1631-1639 (1999) (Abstract).
	Arai et al., "Intrahepatic amino acid and glucose metabolism in a D-galactosamine-induced rat liver failure model," <i>Hepatology.</i> 34: 360-371 (2001) (Abstract).
	Bader et al., "A stable long-term hepatocyte culture system for studies of physiologic processes: cytokine stimulation of the acute phase response in rat and human hepatocytes," <i>Biotech Prog.</i> 8: 219-225 (1992) (Abstract).
	Bauer et al., "Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver," <i>Hepatology.</i> 31: 937-947 (2000) (Abstract).
	Berthiaume et al., "Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: Hepatocytes cultured in a sandwich configuration" <i>FASEB J.</i> 10: 1471-1484 (1996) (Abstract).
	Bhatia et al., "Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts," <i>J Biomed Mat Res.</i> 34: 189-199 (1997) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bhatia et al., "Microfabrication of hepatocyte/fibroblast co-cultures: role of homotypic cell interactions," <i>Biotechnol Prog.</i> 14: 378-387 (1998).
	Bhatia et al., "Probing heterotypic cell interactions: hepatocyte function in microfabricated co-cultures," <i>J Biomater Sci Polym Ed.</i> 9: 1137-1160 (1998) (Abstract).
	Bhatia et al., "Selective adhesion of hepatocytes on patterned surfaces," <i>Ann NY Acad Sci USA.</i> 745: 187-209 (1994) (Abstract).
	Billiar et al., "An L-arginine-dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro," <i>J Exp Med.</i> 169: 1467-1472 (1989) (Abstract).
	Billiar et al., "Kupffer cell cytotoxicity to hepatocytes in coculture requires L-arginine," <i>Arch Surg.</i> 124: 1416-1420 (1989) (Abstract).
	Bonventre, "Kidney ischemic preconditioning," <i>Curr Opin Nephrol Hypertens.</i> 11: 43-48 (2002) (Abstract).
	Bremer et al., "Role of Kupffer cells in the pathogenesis of hepatic reperfusion injury," <i>Am J Physiol.</i> 267: G630-G636 (1994) (Abstract).
	Caraceni et al., "Ischemia-reperfusion injury in rat fatty liver: role of nutritional status," <i>Hepatology.</i> 29: 1139-1146 (1999) (Abstract).
	Caraceni et al., "Rat hepatocytes isolated from alcohol-induced fatty liver have an increased sensitivity to anoxic injury," <i>Hepatology.</i> 25 (4): 943-949 (1997) (Abstract).
	Chan et al., "Metabolic flux analysis of cultured hepatocytes exposed to plasma," <i>Biotechnol Bioeng.</i> 81: 33-49 (2003) (Abstract).
	Chan et al., "Metabolic pre-conditioning of cultured cells in physiological levels of insulin: generating resistance to the lipid-accumulating effects of plasma in hepatocytes," <i>Biotechnol Bioeng.</i> 78: 753-760 (2002) (Abstract).
	Chavez-Cartaya et al., "Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion," <i>Transplantation.</i> 59: 1047-1052 (1995) (Abstract).
	Clemens et al., "Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion," <i>Shock.</i> 8: 80-85 (1997) (Abstract).
	Coito et al., "Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia-reperfusion injury," <i>Transplantation.</i> 74: 96-102 (2002).
	Cursio et al., "A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis," <i>FASEB J.</i> 13: 253-261 (1999) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Delzenne et al., "A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate-fat free diet. Biochemical and morphological analysis," <i>J Hepatol.</i> 26: 880-885 (1997) (Abstract).
	Diaz-Guerra et al., "Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes. Requirement of NF- κ B activation after stimulation with bacterial cell wall products and phorbol esters," <i>J Biol Chem.</i> 271: 30114-30120 (1996) (Abstract).
	Dore et al., "Bilirubin, formed by activation of heme oxygenase-2 protects neurons against oxidative stress injury," <i>Proc Natl Acad Sci USA.</i> 96: 2445-2450 (1999) (Abstract).
	Dunn et al., "Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration," <i>FASEB J.</i> 3: 174-177 (1989) (Abstract).
	Dunn et al., "Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration," <i>Biotechnol Prog.</i> 7: 237-245 (1991) (Abstract).
	Eguchi et al., "Intracellular ATP levels determine cell death fate by apoptosis or necrosis," <i>Cancer Res.</i> 57: 1835-1840 (1997) (Abstract).
	Fink et al., "Metabolism of b-methyl-heptadecanoic acid in the perfused rat heart and liver," <i>J Nucl Med.</i> 31: 1823-1830 (1990) (Abstract).
	Fischman et al., "Muscle protein synthesis by positron-emission tomography with L-[methyl-11C]methionine in adult humans," <i>Proc Natl Acad Sci USA.</i> 27: 12793-12798 (1998) (Abstract).
	Folch and Toner, "Cellular micropatterns on biocompatible materials," <i>Biotechnol Prog.</i> 14: 388-392 (1998) (Abstract).
	Folch and Toner, "Microengineering of cellular interactions," <i>Ann Rev Biomed Eng.</i> 2: 227-256 (2000) (Abstract).
	Folch et al., "Microfabricated elastomeric stencils for micropatterning cell cultures," <i>J Biomed Mater Res.</i> 52: 346-353 (2000) (Abstract).
	Folch et al., "Molding of deep polydimethylsiloxane microstructures for microfluidics and biological applications," <i>J Biomech Eng.</i> 121: 28-34 (1999) (Abstract).
	Fudaba et al., "Geranylgeranylacetone, a heat shock protein inducer, prevents primary graft nonfunction in rat liver transplantation," <i>Transplantation.</i> 72: 184-189 (2001).
	Fudaba et al., "Oral administration of geranylgeranylacetone protects rat livers from warm ischemic injury," <i>Transplant Proc.</i> 31: 2918-2919 (1999).
	Fudaba et al., "Prevention of warm ischemic injury in rat liver transplantation by geranylgeranylacetone," <i>Transplant Proc.</i> 32: 1615-1616 (2000).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Fukumori et al., "The mechanism of injury in a steatotic liver graft during cold preservation," <i>Transplantation</i> . 67: 195-200 (1999) (Abstract).
	Gandhi et al., "Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats," <i>Life Sci</i> . 58: 55-62 (1996) (Abstract).
	Garcia et al., "Hepatic steatosis in liver transplant donors: common feature of donor population?" <i>World J Surg</i> . 22:837-844 (1998) (Abstract).
	Georgopoulos and Welch, "Role of the major heat shock proteins as molecular chaperones," <i>Annu Rev Cell Biol</i> . 9: 601-634 (1993) (Abstract).
	Gerard et al., "Compositional changes in vertebral bone marrow during treatment for acute leukemia: assessment with quantitative chemical shift imaging," <i>Radiology</i> . 183: 39-46 (1992) (Abstract).
	Guidot, "Endotoxin pretreatment in vivo increases the mitochondrial respiratory capacity in rat hepatocytes," <i>Arch Biochem Biophys</i> . 354: 9-17 (1998) (Abstract).
	Gujral et al., "Mechanism of cell death during warm hepatic ischemia-reperfusion in rats: apoptosis or necrosis?" <i>Hepatology</i> . 33: 397-405 (2001) (Abstract).
	Gupta et al., "Ability of insulin to modulate hepatic glucose production in aging rats is impaired by fat accumulation," <i>Am J Physiol Endocrinol Metab</i> . 278: E985-991 (2000) (Abstract).
	Hayashi et al., "The effects of cold preservation on steatotic graft viability in rat liver transplantation," <i>Transplantation</i> . 56: 282-287 (1993) (Abstract).
	Heimberg et al., "Lipoprotein lipid transport by livers from normal and CCI-4-poisoned animals," <i>Am J Physiol</i> . 209: 1053-1060 (1965) (Abstract).
	Higgins et al., "The multi-organ donor. Selection and management," Malden, MA, Blackwell Science. (1997) (Abstract).
	High, <i>Lipid histochemistry</i> . Microscopy Handbook 6. Royal Microscopy Society, Oxford, UK, Oxford University Press (1984) (Abstract).
	Higuchi and Satoh, "Endothelin-1 induces vasoconstriction and nitric oxide release via endothelin ET(B) receptors in isolated perfused rat liver," <i>Eur J Pharmacol</i> . 328: 175-182 (1997) (Abstract).
	Hockenbery et al., "Bcl-2 functions in an antioxidant pathway to prevent apoptosis," <i>Cell</i> . 75: 241-251 (1993) (Abstract).
	Hsu et al., "Measurement of muscle protein synthesis by positron emission tomography with L-[methyl-11C]methionine," <i>Proc Natl Acad Sci USA</i> . 93: 1841-1846 (1996) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Infante et al., "Biosynthesis of plasma lipoproteins by the regenerating liver," <i>Biochim Biophys Acta</i> . 187: 335-344 (1969) (Abstract). [art. in French]
	Jaeschke and Farhood, "Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver," <i>Am J Physiol</i> . 260: G355-G362 (1991) (Abstract).
	Jaeschke et al., "Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia," <i>Am J Physiol</i> . 264: G801-G809 (1993) (Abstract).
	Jaeschke, "Pathophysiology of hepatic ischemia-reperfusion injury: the role of complement activation," <i>Gastroenterology</i> . 107: 583-586 (1994) (Abstract).
	Johnson et al., "Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease," <i>Radiology</i> . 182: 451-455 (1992) (Abstract).
	Kamada and Calne, "Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage," <i>Transplantation</i> . 28: 47-50 (1979) (Abstract).
	Katori et al., "Heme oxygenase-1 system in organ transplantation," <i>Transplantation</i> . 74: 905-912 (2002) (Abstract).
	Kitayama et al., "Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver," <i>Hepatology</i> . 25: 938-942 (1997) (Abstract).
	Koffas et al., "Metabolic engineering," <i>Annu Rev Biomed Eng</i> . 1: 535-557 (1999) (Abstract).
	Kojima et al., "Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins," <i>Anal Chem</i> . 70: 2446-2453 (1998) (Abstract).
	Kondo et al., "Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats," <i>J Surg Res</i> . 60: 36-40 (1996) (Abstract).
	Koneru and Dikdan, "Hepatic steatosis and liver transplantation current clinical and experimental perspectives," <i>Transplantation</i> . 73: 325-330 (2002) (Abstract).
	Koneru et al., "Studies of hepatic warm ischemia in the obese Zucker rat," <i>Transplantation</i> . 59: 942-946 (1995) (Abstract).
	Kumamoto et al., "Kupffer cell-independent acute hepatocellular oxidative stress and decreased bile formation in post-cold-ischemic rat liver," <i>Hepatology</i> . 30: 1454-1463 (1999) (Abstract).
	Kuo et al., "Apoptosis and hepatic allograft reperfusion injury," <i>Clin Transplant</i> . 12 (3): 219-23 (1998) (Abstract).
	Leclercq et al., "Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice," <i>Biochem Biophys Res Commun</i> . 268: 337-344 (2000) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Lee et al., "Metabolic flux analysis of postburn hepatic hypermetabolism," <i>Metabol Eng.</i> 2: 312-327 (2000) (Abstract).
	Lee et al., "Metabolic flux analysis: a powerful tool for monitoring tissue function," <i>Tissue Eng.</i> 5: 347-368 (1999) (Abstract).
	Li et al., "Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color," <i>Exp Cell Res.</i> 222: 28-37 (1996) (Abstract).
	Lichtman and Lemasters, "Role of cytokines and cytokine-producing cells in reperfusion injury to the liver," <i>Sem Liver Dis.</i> 19: 171-187 (1999) (Abstract).
	Liu et al., "Beneficial effects of extracellular glutathione against endotoxin-induced liver injury during ischemia and reperfusion," <i>Circ Shock.</i> 43: 64-70 (1994) (Abstract).
	Liu et al., "NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R," <i>AM J Physio.</i> 275: H2191-H2198 (1998) (Abstract).
	Livni et al., "Beta-methyl[1- ¹¹ C]heptadecanoic acid: a new myocardial metabolic tracer for positron emission tomography," <i>J Nucl Med.</i> 23: 169-175 (1982) (Abstract).
	Loftus et al., "Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors," <i>Science.</i> 288: 2379-2381 (2000) (Abstract).
	Mackay et al., "Ischemic preconditioning reduces infarct volume after subdural hematoma in the rat," <i>Brain Res.</i> 930: 200-205 (2002) (Abstract).
	Marsman et al., "Use of fatty donor liver is associated with diminished early patient and graft survival," <i>Transplantation.</i> 62: 1246-1251 (1996) (Abstract).
	Mato et al., "Heat shock: a barrier to hepatic ischemic injury," <i>J Hepatol.</i> 35: 663-665 (2001).
	Matsumoto et al., "Protective effect of heat preconditioning of rat liver graft resulting in improved transplant survival," <i>Transplantation.</i> 71: 862-868 (2001) (Abstract).
	Matthew et al., "Effects of plasma exposure on cultured hepatocytes: implications for bioartificial liver support," <i>Biotechnol Bioeng.</i> 51: 100-111 (1996) (Abstract).
	Minor et al., "Cold preservation of fatty liver grafts: prevention of functional and ultrastructural impairments by venous oxygen persufflation," <i>J Hepatol.</i> 32: 105-111 (2000) (Abstract).
	Minor et al., "Value of alpha glutathione S-transferase for in vitro evaluation of preservation injury in normal and steatotic livers," <i>Transpl Int.</i> 13 Suppl 1: S551-S554 (2000) (Abstract).
	Murry et al., "Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium," <i>Circulation.</i> 74: 1124-1136 (1986) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Must et al., "The disease burden associated with overweight and obesity," <i>J Am Med Assoc.</i> 282:1523-1529 (1999) (Abstract).
	Nakai et al., "Serial course of left ventricular function, perfusion and fatty acid uptake in the cardiomyopathic hamster," <i>J Nucl Med.</i> 34: 1309-1315 (1993) (Abstract).
	Nakajima et al., "The effect of carnitine on ketogenesis in perfused livers from juvenile visceral steatosis mice with systemic carnitine deficiency," <i>Pediatr Res.</i> 42: 108-113 (1997) (Abstract).
	Nakano et al., "The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet," <i>Hepatology.</i> 26: 670-678 (1997) (Abstract).
	Noda and Okita, "Fatty liver due to disproportionally added methionine to a low soybean diet and lipotropic action of phosphatides in rats," <i>J Nutr.</i> 110: 505-512 (1980) (Abstract).
	Ogawa et al., "Renal denervation abolishes the protective effects of ischaemic preconditioning on function and haemodynamics in ischaemia-reperfused rat kidneys," <i>Acta Physiol Scand.</i> 174: 291-297 (2002) (Abstract).
	Papoutsakis, "Equations and calculations for fermentations of butyric acid bacteria," <i>Biotechnology Bioeng.</i> 26: 174-187 (1984) (Abstract).
	Peralta et al., "Hepatic preconditioning preserves energy metabolism during sustained ischemia," <i>Am J Physiol Gastrointest Liver Physiol.</i> 279: G163-171 (2000) (Abstract).
	Powers et al., "Exercise, heat shock proteins, and myocardial protection from I-R injury," <i>Med Sci Sports Exerc.</i> 33: 386-392 (2001) (Abstract).
	Qian et al., "Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes," <i>Am J Physiol.</i> 273: C1783-C1792 (1997) (Abstract).
	Quarfordt et al., "Effect of apolipoproteins on the induction of hepatic steatosis in rats," <i>Gastroenterology.</i> 80: 149-153 (1981) (Abstract).
	Raeburn et al., "Organ preconditioning," <i>Arch Surg.</i> 136: 1263-1266 (2001) (Abstract).
	Redaelli et al., "Extended preservation of rat liver graft by induction of heme oxygenase-1," <i>Hepatology.</i> 35: 1082-1092 (2002).
	Reers et al., "Mitochondrial membrane potential monitored by JC-1 dye," <i>Methods Enzymol.</i> 260: 406-417 (1995) (Abstract).
	Reinehr et al., "Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin-1," <i>Hepatology.</i> 28: 1566-1577 (1998) (Abstract).
	Rejda et al., "Brain tolerance and preconditioning," <i>Pol J Pharmacol.</i> 53: 73-79 (2001) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Roheim et al., "Alterations of lipoprotein metabolism in orotic acid-induced fatty liver," <i>Am J Pharm Sci Support Public Health</i> . 15: 21-26 (1966) (Abstract).
	Rosen et al., "Hematologic bone marrow disorders: quantitative chemical shift MR imaging," <i>Radiology</i> . 169: 799-804 (1988) (Abstract).
	Rosen et al., "Proton chemical shift imaging: an evaluation of its clinical potential using an in vivo fatty liver model," <i>Radiology</i> . 154: 469-472 (1985) (Abstract).
	Rossi et al., "Liver transplantation: expanding the donor pool," <i>Transplant Proc</i> . 33: 1307-1309 (2001) (Abstract).
	Rotem et al., "Oxygen uptake rates in cultured hepatocytes," <i>Biotechnol Bioeng</i> . 40: 1286-1291 (1992) (Abstract).
	Salaspuro, "Ethanol inhibition of galactose oxidation as related to the redox state of the fatty liver," <i>Scand J Clin Lab Invest Suppl</i> . 18:145-147 (1966) (Abstract).
	Salvioli et al., JC-1, but not DiOC ₆ (3) or rhodamine 123, is a reliable fluorescent probe to assess $\Delta\Phi$ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis," <i>FEBS Lett</i> . 411: 77-82 (1997) (Abstract).
	Samarasinghe and Farrell, "The central role of sinusoidal endothelial cells in hepatic hypoxia-reoxygenation injury in the rat," <i>Hepatology</i> . 24: 1230-1237 (1996) (Abstract).
	Schmitz-Feuerhake et al., "Determination of the specific blood flow of the liver by inhalation of radioactive rare gases," <i>Acta Hepatogastroenterol</i> . 22: 150-158 (1975) (Abstract).
	Seifalian et al., "The effect of graded steatosis on flow in the hepatic parenchymal microcirculation," <i>Transplantation</i> . 68: 780-784 (1999) (Abstract).
	Selzner and Clavien, "Fatty liver in liver transplantation and surgery," <i>Semin Liver Dis</i> . 21: 105-113 (2001) (Abstract).
	Selzner et al., "Mechanisms of ischemic injury are different in the steatotic and normal rat liver," <i>Hepatology</i> . 32: 1280-1288 (2000) (Abstract).
	Serafin et al., "Ischemic preconditioning increases the tolerance of Fatty liver to hepatic ischemia-reperfusion injury in the rat," <i>Am J Pathol</i> . 161: 587-601 (2002).
	Shimabukuro et al., "Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1 β cytotoxicity," <i>J Clin Invest</i> . 100: 1750-1754 (1997) (Abstract).
	Shimabukuro et al., "Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression," <i>J Biol Chem</i> . 273: 32487-32490 (1998) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/531,001
(37 C.F.R. § 1.98(b))		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Shimabukuro et al., "Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression," <i>Prc Natl Acad Sci USA</i> . 95: 9558-9561 (1998) (Abstract).
	Shiratori et al., "Modulation of ischemia-reperfusion-induced hepatic injury by Kupffer cells," <i>Dig Dis Sci</i> . 39: 1265-1272 (1994) (Abstract).
	Shito et al., "A fulminant hepatic failure model in the rat: involvement of interleukin-1 β and tumor necrosis factor- α ," <i>Dig Dis Sci</i> . 46: 1700-1708 (2001) (Abstract).
	Shito et al., "Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat," <i>Transplantation</i> . 63: 143-148 (1997) (Abstract).
	Sindhi et al., "Impact of segmental grafts on pediatric liver transplantation – a review of the United Network for Organ Sharing Scientific Registry data (1990-1996)," <i>J Ped Surg</i> . 34: 107-110 (1999) (Abstract).
	Sola et al., "Protective effect of ischemic preconditioning on cold preservation and reperfusion injury associated with rat intestinal transplantation," <i>Ann Surg</i> . 234: 98-106 (2001) (Abstract).
	Spolarics and Meyenhofer, "Augmented resistance to oxidative stress in fatty rat livers induced by a short-term sucrose-rich diet," <i>Biochim Biophys Acta</i> . 1487: 190-200 (2000) (Abstract).
	Stefanovich et al., "Extracorporeal plasma perfusion of cultured hepatocytes: effect of intermittent perfusion on hepatocyte function and morphology," <i>J Surg Res</i> . 66: 57-63 (1996) (Abstract).
	Stephanopoulos et al., "Metabolic engineering: principles and methodologies," San Diego: Academic Press (1998) (Abstract).
	Strasberg et al., "Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation," <i>Hepatology</i> . 20: 829-838 (1994) (Abstract).
	Sumimoto et al., "24-hour rat liver preservation using UW solution and some simplified variants," <i>Transplantation</i> . 48: 1-5 (1989) (Abstract).
	Tahara et al., "Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats," <i>J Clin Invest</i> . 103: 313-320 (1999) (Abstract).
	Teramoto et al., "A rat fatty liver transplant model," <i>Transplantation</i> . 55: 737-741 (1993) (Abstract).
	Teramoto et al., "In vivo microscopic observation of fatty liver grafts after reperfusion," <i>Transplant Proc</i> . 26: 2391 (1994) (Abstract).
	Tilles et al., "Critical issues in bioartificial liver development," <i>Technol Health Care</i> . 10: 177-186 (2002) (Abstract).
	Tilles et al., "Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor," <i>Biotechnol Bioeng</i> . 73: 379-389 (2001) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/434002
	Serial No.	10/531,001
	Applicant	Berthiaume et al.
	Filing Date	Nov. 10, 2005
	Group	3736
	IDS Filed	December 13, 2006

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Tonsgard et al., "Binding of straight-chain saturated dicarboxylic acids to albumin," <i>J Clin Invest.</i> 82: 1567-1573 (1988) (Abstract).
	Torres-Duran et al., "Studies on the preventive effect of <i>Spirulina maxima</i> on fatty liver development induced by carbon tetrachloride, in the rat," <i>J Ethnopharmacol.</i> 64: 141-147 (1999) (Abstract).
	Tsai and Lee, "Application of metabolic pathway stoichiometry to statistical analysis of bioreactor measurement data," <i>Biotechnol Bioeng.</i> 32: 713-715 (1988) (Abstract).
	Uchinami et al., "Effect of heat shock preconditioning on NF-kappaB/I-kappaB pathway during I/R injury of the rat liver," <i>Am J Physiol Gastrointest Liver Physiol.</i> 282: G962-G971 (2002) (Abstract).
	Unger et al., "Regulation of fatty acid homeostasis in cells: novel role of leptin," <i>Proc Natl Acad Sci USA.</i> 96: 2327-2332 (1999) (Abstract).
	Vaisler, "Technic of liver isolated and perfused in vitro in the study of some problems of endocrinology," <i>Stud Cercet Endocrinol.</i> 19: 3-13 (1968) (Abstract). [art. in Romanian]
	Varma and Palsson, "Metabolic-Flux Balancing: Basic Concepts, Scientific and Practical Use," <i>Bio/Technology.</i> 12: 994-998 (1994) (Abstract).
	Vogt et al., "A general model for analysis of the tricarboxylic acid cycle with use of [¹³ C]glutamate isotopomer measurements," <i>Am J Physiol.</i> 266: E1012-E1022 (1994) (Abstract).
	Vogt et al., "TCA cycle flux estimates from NMR- and GC-MS-determined [¹³ C]glutamate isotopomers in liver," <i>Am J Physiol.</i> 272: C2049-C2062 (1997) (Abstract).
	Wang and Stephanopoulos, "Application of macroscopic balances to the identification of gross measurement errors," <i>Biotechnol Bioeng.</i> 25: 2177-2208 (1983) (Abstract).
	Washizu et al., "Amino acid supplementation improves cell-specific functions of the rat hepatocytes exposed to human plasma," <i>Tissue Eng.</i> 6: 497-504 (2000) (Abstract).
	Washizu et al., "Long-term maintenance of cytochrome P450 activities by rat hepatocyte/3T3 cell co-cultures in heparinized human plasma," <i>Tissue Eng.</i> 7: 691-703 (2001) (Abstract).
	Washizu et al., "Optimization of rat hepatocyte culture in citrated human plasma," <i>J Surg Res.</i> 93: 237-246 (2000) (Abstract).
	Yamagami et al., "Heat shock preconditioning ameliorates liver injury following normothermic ischemia-reperfusion in steatotic rat livers," <i>J Surg Res.</i> 79: 47-53 (1998) (Abstract).
	Yamaguchi et al., "Effect of burn injury on glucose and nitrogen metabolism in the liver: Preliminary studies in a perfused liver system," <i>Surgery.</i> 121: 295-303 (1997) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/434002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/531,001
		Applicant	Berthiaume et al.
		Filing Date	Nov. 10, 2005
		Group	3736
		IDS Filed	December 13, 2006
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Yang and Brunengraber, "Glutamate, a window on liver intermediary metabolism," <i>J Nutr.</i> 130: 991S-994S (2000) (Abstract).
	Yarmush et al., "Cutaneous burn injury alters relative tricarboxylic acid cycle fluxes in rat liver," <i>J Burn Care Rehabil.</i> 20: 292-302 (1999) (Abstract).
	Yarmush et al., "Hepatic tissue engineering. Development of critical technologies," <i>Ann NY Acad Sci.</i> 665: 238-252 (1992) (Abstract).
	Yeh et al., "Xenon-133 hepatic retention ratio: a useful index for fatty liver quantification," <i>J Nucl Med.</i> 30: 1708-1712 (1989) (Abstract).
	Yen et al., "Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase," <i>FASEB J.</i> 13: 135-142 (1999) (Abstract).
	Yokoyama et al., "Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion," <i>Shock.</i> 13: 72-78 (2000) (Abstract).
	Yonezawa et al., "Suppression of tumor necrosis factor-alpha production and neutrophil infiltration during ischemia-reperfusion injury of the liver after heat shock preconditioning," <i>J Hepatol.</i> 35: 619-627 (2001).
	Yoshioka et al., "Hepatic venous hemoglobin oxygen saturation predicts regenerative status of remnant liver after partial hepatectomy in rats," <i>Hepatology.</i> 27: 1349-1353 (1998) (Abstract).
	Zaknun et al., "Effect of monounsaturaton of a branched fatty acid on organ selectivity," <i>J Nucl Med.</i> 36: 2062-2068 (1995) (Abstract).
	Zaman et al., "Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion," <i>Biopharm Drug Dispos.</i> 18: 803-819 (1997) (Abstract).
	Zhou et al., "Lipotoxic heart disease in obese rats: implications for human obesity," <i>Proc Natl Acad Sci USA.</i> 97: 1784-1789 (2000) (Abstract).
	Zupke et al., "Intracellular flux analysis applied to the effect of dissolved oxygen on hybridomas," <i>Appl Microbiol Biotechnol.</i> 44: 27-36 (1995) (Abstract).
	Zupke et al., "Metabolic effects of stress mediators on cultured hepatocytes," <i>Biotechnol Bioeng.</i> 58: 222-230 (1998) (Abstract).
	Zupke et al., "Numerical isotopomer analysis: estimation of metabolic activity," <i>Anal Biochem.</i> 247: 287-293 (1997) (Abstract).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	